Cell and Gene Manufacturing and Logistics

  1. Emerging Manufacturing Technologies For Cell Therapies | Audience Q&A 4/15/2025

    Cell & Gene Live’s Audience Q&A always draws valuable questions in real time from our audience. Rohit Ingale, Head of Manufacturing & MSAT, Arcellx and David O’Donnell, Vice President, Head of Manufacturing, Vor Bio provide detailed responses to audience questions that addressed the importance of vein-to-vein time for non-cancer indications, such as autoimmune diseases.

  2. The Impact Of Cell Therapy Manufacturing On Patient Access And Experience 4/15/2025

    During this segment of Cell & Gene Live, expert panelists, Rohit Ingale, Head of Manufacturing & MSAT, Arcellx and David O’Donnell, Vice President, Head of Manufacturing, Vor Bio share why improvements in cell therapy manufacturing directly impact the patient experience.

  3. Implementing Emerging Manufacturing Technologies For Cell Therapies 4/15/2025

    In this segment of Cell & Gene Live, Rohit Ingale, Head of Manufacturing & MSAT, Arcellx and David O’Donnell, Vice President, Head of Manufacturing, Vor Bio emphasize the importance of focusing on solving the problem at hand when adopting new technologies.

  4. Emerging Technologies In Cell Therapy Manufacturing: Embracing Automation, Robotics, And AI 4/15/2025

    In this segment of our Cell & Gene Live, expert panelists Rohit Ingale, Head of Manufacturing & MSAT, Arcellx and David O’Donnell, Vice President, Head of Manufacturing, Vor Bio define innovation as benefiting patients and emphasize automation and robotics as central to the cause.

  5. Cell Therapy's Current Manufacturing Challenges 4/15/2025

    In this segment, Cell & Gene’s Chief Editor, Erin Harris, welcomes the audience and introduces the expert panelists, Rohit Ingale, Head of Manufacturing & MSAT, Arcellx and David O’Donnell, Vice President, Head of Manufacturing, Vor Bio.

  6. Pioneers And Visionaries: Cell Line Development And AAV Gene Therapy 4/15/2025

    Viral vector-based gene therapies offer hope for treating rare genetic disorders and complex conditions. Discover an advanced AAV producer cell line that is revolutionizing scalable, efficient, and accessible gene therapy production.

  7. How CAR-NKs Offer Powerful Therapeutic Flexibility 4/15/2025

    Induced pluripotent stem cells have emerged as a promising platform for producing CAR-engineered NK cells in a standardized, renewable, and scalable way.

  8. Ramping Up GMP-Compliant CAR-NK Manufacturing At Scale With iPSCs 4/15/2025

    The ability to produce billions of NK cells in a single production run represents a transformative shift in the economics and logistics of cell therapy.

  9. Pharmaceutical Sovereignty: The Resilience We Cannot Outsource 4/15/2025

    Pharmaceutical sovereignty is no longer a theoretical concern. Sovereignty in this context does not imply isolation, but rather strategic resilience: building robust national and regional capabilities that ensure security while enabling global collaboration. 

  10. Control Strategies And Method Development For Nitrosamines In APIs And Drug Products 4/15/2025

    Explore regulatory insights, analytical strategies, and real-world case studies for effective nitrosamine control in APIs and drug products.